NDES
Breast Cancer
Key Facts
About Continuity Biosciences
Continuity Biosciences is an early-stage biotech innovator building a portfolio of precision drug delivery platforms designed to enhance the efficacy and safety of existing and emerging therapies. The company's core strategy involves creating implantable and localized systems—such as the NICHE platform for cell therapy and iontophoretic devices for targeted chemotherapy—that protect therapeutics and maximize impact at the disease site while minimizing systemic exposure. With a focus on significant unmet needs in Type 1 diabetes, pancreatic cancer, HIV, and other conditions, Continuity is positioning itself at the intersection of advanced engineering and deep biological insight. The company has secured strategic investment from Breakthrough T1D to advance its lead program toward human trials.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |